Getting Glemba approved through the next phase will be critical. FDA approval appears on target, and if that happens, I think a $5-$7 PPS will occur almost immediately. The days of $30 per share are in the mirror for now. Yes, the pipeline looks very promising, but the company will need to burn cash for R & D. That will keep the PPS from reaching such lofty levels until the company has at least 2 to 3 drugs actually approved by the FDA with promises of additional revenues pouring in. Under that scenario, and assuming CLDX continues to successfully go this alone, $30 might even look cheap! All IMO.
CLDX$$$$
News 
Market Data 
Discover 
